Clinical Scorecard: Prostate Cancer Screening: A Historical Perspective, Current Status, and Future Directions

At a Glance

Key Highlights

• PSA test approved in 1986 for monitoring recurrence; later used for screening.
• USPSTF recommended against routine PSA screening for all men in 2012 due to overdetection concerns.
• Revised guidelines in 2018 endorse individualized decision-making for men aged 55 to 69.
• Shorter screening intervals and earlier initiation may reduce metastatic disease risk.
• Active surveillance is a strategy to avoid overtreatment but has limitations.

Guideline-Based Recommendations

Diagnosis

• PSA screening should be considered based on individual risk factors.

Management

• Shared decision-making is essential in determining the need for screening.

Monitoring & Follow-up

• Active surveillance for low-risk prostate cancer with regular PSA tests and biopsies.

Risks

• Potential harms include overdetection, unnecessary biopsies, and adverse treatment outcomes.

Patient & Prescribing Data

Veterans receiving prostate needle biopsy between 2015 and 2023.

Younger initiation of screening and shorter intervals may be beneficial.

Clinical Best Practices

• Implement risk-based screening strategies to target high-risk individuals.
• Encourage shared decision-making discussions between clinicians and patients.

Related Resources & Content

• Siavoshi et al.
• US Preventative Services Task Force (USPSTF)
• European Randomized Study of Screening for Prostate Cancer (ERSPC)